Volume 26, Number 5—May 2020
Research
Zika Virus Circulation in Mali
Table 3
Study site and year | Total no. | IgG* doubtful, no. (%) | IgG* positive, no. (%) | VNT† positive, no. (%) |
---|---|---|---|---|
Niono 2016 | 65 | 4 (6 0.2) | 4 (6.2) | 2 (3.1) |
Bamako 2016 | 129 | 0 (0.0) | 11 (8.5) | 7 (5.4) |
Bamako 2013‡ | 637 | 18 (2.8) | 67 (10.5) | 47 (7.4) |
Kadiolo 2016 | 136 | 14 (10.3) | 22 (16.2) | 14 (10.3) |
Bougouni 2016 | 127 | 3 (2.4) | 22 (17.3) | 15 (11.8) |
Kita 2016 | 40 | 5 (12.5) | 7 (17.5) | 6 (15.0) |
Bandiagara 2016 | 187 | 24 (12.8) | 81 (43.3) | 29 (15.5) |
Diéma 2016 |
109 |
14 (12.8) |
39 (35.8) |
22 (20.2) |
Total | 1,430 | 82 (5.7) | 253 (17.7) | 142 (9.9) |
*Result by Euroimmun IgG ELISA assay.
†Result by cytopathic effect-based virus neutralization test.
‡Volunteer blood donors.
1These authors contributed equally to this article.
2Deceased.
Page created: April 16, 2020
Page updated: April 16, 2020
Page reviewed: April 16, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.